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Abstract: After Edward Jenner established human vaccination over 200 years ago, attenuated 
poxviruses became key players to contain the deadliest virus of its own family: Variola virus 
(VARV), the causative agent of smallpox. Cowpox virus (CPXV) and horsepox virus (HSPV) 
were extensively used to this end, passaged in cattle and humans until the appearance of vaccinia 
virus (VACV), which was used in the final campaigns aimed to eradicate the disease, an 
endeavor that was accomplished by the World Health Organization (WHO) in 1980. Ever since, 
naturally evolved strains used for vaccination were introduced into research laboratories 
where VACV and other poxviruses with improved safety profiles were generated. 
Recombinant DNA technology along with the DNA genome features of this virus family 
allowed the generation of vaccines against heterologous diseases, and the specific insertion and 
deletion of poxvirus genes generated an even broader spectrum of modified viruses with new 
properties that increase their immunogenicity and safety profile as vaccine vectors. In this 
review, we highlight the evolution of poxvirus vaccines, from first generation to the current 
status, pointing out how different vaccines have emerged and approaches that are being followed 
up in the development of more rational vaccines against a wide range of diseases. 








The most deadly poxvirus, VARV, was the agent that caused smallpox, a fatal disease for which 
records go back more than 3500 years [1] and which is suspected to have emerged in 10,000 BCE [2]. 
Since then, the virus has spread from person to person and from country to country, causing the most 
severe epidemics in human history, with a death rate of about 30% of those infected. More than 30 years 
have elapsed since WHO declared smallpox eradicated, but this achievement would have been impossible 
without the discovery of vaccination and the evolution of poxviruses as vaccines. 
The first strategy aiming to fight the smallpox disease was the use of VARV itself as the immunization 
agent. Variolation, an oriental practice that consisted of inoculating small amounts of material from an 
infected person to a healthy individual to prevent a natural infection, was used for centuries in the Orient 
and introduced in Europe by the physician Emmanuel Timoni [3], who described the technique in 1714;  
the practice was later introduced by Lady Mary Wortley Montagu in the United Kingdom in 1721 [4]. 
In 1798 the English physician Edward Jenner established a much safer practice, demonstrating that 
another poxvirus, CPXV—which infected cattle—could be used to prevent smallpox infections in 
humans. This procedure became known as vaccination, derived from “vacca,” the Latin word for cow. 
In 1881 Louis Pasteur proposed that vaccination should be the generic term used for preventive 
inoculations against any animal or human diseases [5]. 
From 1803 to 1806 the Jennerian vaccination practices and viral strains were expanded to the New 
World in the Royal Philanthropic Expedition of the Vaccine carried out by the Spanish surgeon 
Francisco Xavier Balmis, in a programmed expedition under the auspices of King Carlos IV of Spain. 
In this first expedition in 1803 in the ship María Pita, the vaccine was transported to America through 
arm-to-arm propagation in 22 orphan children. At La Guayra (now Venezuela) the expedition was 
divided into two groups, one under Salvany, who extended vaccination to South America, and the other 
led by Balmis, who continued to Cuba and Mexico. From Acapulco the vaccine traveled to Manila  
(in the Philippines) and then from Macau into China [6,7]. The Spanish expedition was the first-ever 
mass vaccination campaign, 150 years before the WHO was established. The expedition was successful, 
and Jenner wrote: “I don’t imagine the annals of history furnish an example of philanthropy so noble,  
so extensive as this.” 
Over time, CPXV and also HSPV were passed through cattle, rabbits, horses and humans and used 
for vaccinating against smallpox all over the globe. However, at a certain evolutionary point, those 
viruses were superseded by VACV, another poxvirus whose origin remains unknown, but which 
eventually became the most studied poxvirus and has been used extensively as a research tool.  
The latter half of the 19th century saw the emergence of microbiology and immunology as scientific 
disciplines. Many of the pioneers in these new sciences used VACV for their studies and vaccine 
production was introduced into laboratories and taken over by scientists rather than local physicians. This 
entailed an improvement in the quality of the vaccines, the methods for the distribution and the public 
health infrastructure, which led to the elimination of endemic smallpox from the industrialized countries 
of Europe and North America by the early 1950s [8]. Modifications to traditional production and 
international quality control of vaccines were introduced shortly after the Intensified Smallpox 
Eradication Program in 1967. Thanks to this program, the last natural case of smallpox occurred in 
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Somalia in 1977, and in 1980 the WHO declared the disease eradicated [9]. To date, smallpox is the only 
human infectious disease that has been successfully eradicated.  
In the early 1980s, recombinant DNA technology revolutionized molecular biology, allowing the 
insertion of foreign DNA into poxvirus genomes. Early studies by Woodroffe and Fenner indicated in 
1960 that homologous recombination could occur between the genomes of two replicating poxviruses [10]. 
Twenty-two years later, marker rescue studies demonstrated that fragments of genomic [11] and  
cloned [12] DNA could recombine with the genome of VACV in infected cells. Furthermore, poxvirus 
expression vectors were described simultaneously in 1982 by the laboratories of Enzo Paoletti [13] and 
Bernard Moss [14], and recombinant DNA technology quickly became widely used for vaccine 
development as well as for research in numerous other fields. Thus, the ability to insert heterologous 
genes into poxvirus genomes deeply improved their vaccination capabilities. Poxviruses were no longer 
used only as successful smallpox vaccines, but also as vaccines against a wide range of heterologous 
diseases, namely the hepatitis B surface antigen [15], the hemagglutinin of the influenza virus [16,17], 
the glycoprotein D of herpes virus [18] and the rabies virus glycoprotein [19], the first foreign  
antigens and heterologous diseases explored. It is of importance that, as all chordopoxviruses have  
a similar arrangement of genes, interchangeable promoters and conserved RNA polymerase and 
transcription factors, the principles developed for VACV expression vectors could be applicable to other 
poxviruses [20].  
In 1990, the genome sequencing of Copenhagen, one of the most studied strains of vaccinia,  
was published by Paoletti and co-workers [21]. With this knowledge and the ability to insert and delete 
selective genes, poxviruses have been modified à la carte in order to improve their safety and 
immunogenicity or even their ability to selectively kill tumor cells.  
In this article, we review how different poxviruses have evolved in nature and in controlled laboratory 
environments to generate a wide variety of strains that are being used as vaccine candidates against 
homologous diseases such as smallpox, heterologous diseases such as rabies, HIV/AIDS, hepatitis C, 
tuberculosis, malaria and leishmaniasis, among others, or against other complex diseases like cancer. 
We describe the sequences by which different poxvirus-based vaccines evolved with time, and how 
genetic manipulation of the poxvirus genome led to the development of vaccine candidates with wide 
application against human and animal diseases. 
2. Origin of Vaccination: Cowpox/Horsepox Controversy upon Original Vaccinia Strain 
In order to trace, step-by-step, the evolution of poxviruses as vaccine vectors, one of the starting 
points should be the identification of the original virus used by Jenner and colleagues at early stages of 
vaccination. In 1796 Jenner vaccinated an eight-year-old boy, James Phipps, with a cowpox lesion from 
the milkmaid Sarah Nelmes and proved it was effective after challenge against smallpox [22]. From that 
experiment, the practice of arm-to-arm vaccinations in humans expanded around the world, using cattle to 
amplify the viral stocks. However, vaccination with the feasible original CPXV was displaced, eventually, 
with VACV, whose natural host and origin has not been identified yet. 
Several hypotheses arose in the past about the origin of VACV and its derivation from the original 
“variolae vaccinae.” It had been proposed that VACV could have derived from VARV, from CPXV,  
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or could be a hybrid of VARV and CPXV viruses that had been genetically selected after the use of 
contaminated vaccine [23].  
VARV could have been altered and transformed into VACV after several years of vaccination from 
human to human or during passages in animals, but VARV host range genes and studies in animals 
indicate that this hypothesis should be dismissed [24,25]. VARV has a restricted human replication 
phenotype that contrasts with the wide host range of VACV [26]. On the other hand, CPXV probably 
exhibits the broadest host range and the greatest genetic diversity among these poxviruses. Nonetheless, 
originally the differences between CPXV and VACV were considered too great to make that origin 
probable [27], and more recent DNA sequencing data follow the same thread of thought [28]. 
Several factors exacerbated the difficulty of identifying the origin of VACV. The old smallpox 
vaccines were rarely subjected to clonal purification, and those methods of propagation produced 
mixtures of viruses called quasispecies [29]. In fact, deep genome sequencing has suggested that modern 
vaccines are comprised of a complex mixture of different vaccinia viruses [30,31]. Furthermore, the 
practice of co-cultivating smallpox vaccines with other viruses, including VARV, could have produced 
recombinant viruses and obscured the origin of VACV strains [8]. In this context, there are few evidences 
of horizontal gene transfer between orthopoxviruses. One example is the presence of two CPXV-like 
genes in the Lister VACV strain [32], and another one is represented by a small region of sequence-
encoding HSPV-like single nucleotide polymorphisms (SNPs) in the DPP17 Dryvax subclone [29]. 
Among orthopoxviruses, CPXV isolates—which can be split into five different monophyletic 
lineages—have the largest genomes, averaging 220 kbp, around 30 kbp larger than VACV; only the 
genome of HSPV is larger than 200 kbp [33]. These five subtypes of CPXV encode all of the genes 
present in all other orthopoxviruses, leading to the suggestion that the modern orthopoxviruses have 
evolved from CPXV through reductive evolution [34]. 
Historic literature states that the original vaccine strains were derived from CPXV samples; however, 
Edward Jenner also believed that his vaccine was originally the agent that caused an infection in the 
heels of horses that he called “grease” and that was suitable for human use after passaging through  
cows [22,23]. It has also been argued that it could be possible that Jenner confused “grease” (dermatitis 
verrucosa) with horsepox (variola equina). In fact, equination was used side by side with vaccination at 
the early stages of smallpox epidemics. There are several examples of early vaccination with HSPV,  
for example by Dr. De Carro in Vienna or Dr. Sacco in Milan, who communicated the practice to  
Jenner [35,36], or by Dr. Loy, who also showed that horses were susceptible to a poxvirus that conferred 
immunity. Both CPXV and HSPV caused the human immune system to react as if it has been exposed to 
the smallpox virus, creating long-term immunity because all orthopoxviruses are antigenically related 
and immunization with nearly any orthopoxvirus can protect against challenge with another 
orthopoxvirus [37]. 
Phylogenetic analysis of the conserved regions of poxvirus genomes indicated that HSPV is closely 
related to sequenced isolates of VACV and rabbitpox virus [38]. Furthermore, it is of interest that 
experimental infection of horses with VACV produces clinical signs of HSPV [39].  
In the most recent article studying poxvirus evolution, the authors claim that the most probable route 
by which VACV strains might have evolved is from a stock of virus containing an ancestral HSPV-like 
virus. This conclusion arose after identifying a gene, DVX_213, which seems to have been subject to 
widespread negative selection in VACV strains [28]. Nonetheless, in order to better understand the 
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relationship between HSPV and VACV it is important to obtain more genomic sequencesofHSPV,  
an endeavor that is extremely challenging because HSPV seems to be extinct [5].  
3. First-Generation VACV Vaccines and the Global Smallpox Eradication Campaign 
Vaccination is a procedure that has been performed for over 200 years in different countries around 
the world and without international standardization. In fact, reliable assay methods for quality control 
were not developed until the 1950s and not implemented until the 1960s. As a consequence, the VACV 
strains used in different countries differed in their biological properties [8]. These first VACV strains 
received their names regarding the health agency or the country or region of origin and the most 
widelyused are summarized in Table 1. In addition, a large number of manufacturers—71 distributed 
around the world—were involved in the global effort to eradicate smallpox.  
Table 1. List of the different VACV strains used in the global smallpox eradication campaign. 
VACV Strain Country or Region of Application 
New York City Board of Health (NYCBH) USA 
Lister  UK, Europe, Asia, Africa, USA 
Temple of Heaven (Tian Tan) China 
Ecuador-Moscow 1963 (EM-63) Union of Soviet Socialist Republics (USSR), India 
Tashkent USSR 
B-15 USSR 
Bern Germany, Austria 




In the United States all the vaccines against smallpox were derived from a stock supplied to the New 
York City Health Department in 1856, NYCBH. Using this strain, Dr. Rivers developed two attenuated 
strains of the virus, CVI-78 and CVII, by passing NYCBH through rabbit testes and chick embryos [40]. 
These caused less reactogenicity in comparison with the parental strain, but their ability to mediate 
protection against smallpox was questioned [41,42]. This strain was also distributed to other laboratories, 
where it received different names, such as IHD, LED-0, Noguchi or WR. It was passaged in different 
organs such as the brain or testes of rabbits or mice, thus modifying its biological properties. Several studies 
showed that strains such as WR or IHD presented increased levels of pathogenicity [43] and adverse effects 
in humans, limiting their use as vaccines of choice in the early steps of the fight against smallpox [8]. 
Another vaccine was derived from NYCBH after 22 to 28 passages in cows in Wyeth Laboratories 
(Marietta, PA, USA). This vaccine was called Dryvax® and is a non-clonal vaccine that was prepared in 
calf lymph and distributed as a freeze-dried vaccine. The nature of non-clonal origin of Dryvax® has been 
recently characterized. Genetic analysis shows that Dryvax® is a complex of different VACV sub-strains 
that has been classified in four subgroups according to genome structure analysis [29]. This vaccine is still 
one of the current USA-licensed smallpox vaccines. 
A second vaccine derived from NYCBH and licensed in the USA is Aventis Pasteur Smallpox 
Vaccine (APSV). APSV was manufactured from 1956 to 1957 and was maintained as a frozen 
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preparation, but clinical studies with this vaccine were stopped when myocarditis cases arose in the 
vaccination trials [44].  
NYCBH was also believed to be the parental strain of EM-63 vaccine, a strain derived from  
Ecuador that was used in the former USSR and was also widely used in the eradication of smallpox in 
India [45,46]. 
The Lister strain, prepared on the skin of sheep, was widely used for vaccination against smallpox 
from 1892 because it produced pocks on the chorioallantoic membrane that were easier to count in 
comparison with the other VACV strains, and because the WHO International Reference Center later 
produced seed lots of this strain for distribution to vaccine producers in developing countries [8]. The 
commercial Lancy-Vaxina (Berna Biotech) is derived from this strain, and the formulation of the vaccine 
is a lyophilized product prepared from calf lymph [47]. 
Tian Tan virus was the most extensively VACV strain used to vaccinate against smallpox in China 
since 1926. The name of “Tian Tan” was acquired because the virus was isolated in Beijing’s Temple 
of Heaven, where the Central National Epidemic Bureau was initially housed. The virus was used in China 
from 1926 to 1954 and from 1960 to 1980, being the Russian strain of vaccinia used between 1955 and 
1960 [48]. The legend tells that the vaccine was isolated by Mr. Qi Changqing from a patient with 
smallpox and then passaged in the skin of monkeys, rabbits and cows. However, this story lacks scientific 
credibility because VARV infection is restricted to humans and does not contain the host range genes 
needed to infect monkeys, rabbits or cows. Moreover, recent genomic sequencing demonstrates that Tian 
Tan is clearly a VACV that shares a common origin with Copenhagen strain, and it is different from 
monkeypox (MPXV), VARV or HSPV [48].  
The intensified Eradication Campaign against smallpox started in 1967 and no particular strain was 
officially recommended but, in response to inquiries, the Smallpox Eradication Unit advised that either 
the Lister or the NYCBH strains should be used. Additionally, the potency and safety of the different 
vaccines were standardized; lyophilization was recommended and vaccine batches might contain at least 
1 × 108 pock-forming units per mL [8]. Other VACV strains used in early vaccination campaigns against 
smallpox were Ankara (used in Turkey), Aosta (Italy), Bohemia (Czechoslovakia), Bordeaux (Africa 
and Portugal), Massachusetts 999 (Argentina), Gam (USSR), MRIVP (USSR), Per (USSR), Williamsport 
(USA), LMC (UK), Hamburg (Germany), Sweden (Sweden), Finland (Finland), Patwadanger (India), 
Vienna (Bulgaria), Spain (Spain), Tom (USSR) and Chambon (France and Africa) [8,49]. 
The last natural infection of smallpox occurred in Somalia in 1977. Eradication was possible due to 
vaccination, but also because to date no animal reservoir for smallpox other than humans exists [50]. 
Since the eradication, VARV is officially retained at two WHO collaborative centers: the Centers for 
Disease Control and Prevention (CDC), in Atlanta (Georgia, USA), and the State Research Center of 
Virology and Biotechnology (VECTOR), in Novosibirsk (Russian Federation). 
Although smallpox has been eradicated as a public health threat it could potentially reemerge as  
a bioterrorist threat. The risk scenario includes other animal poxviruses and genetically engineered 
manipulations of poxviruses. Thus, for preventing this potential risk and due to the side effects of  
the first-generation VACV vaccines, safer VACV strains had to be improved and developed for the  
post-eradication era. 
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4. Second-Generation VACV Vaccines 
In order to standardize procedures, control possible microbial contamination and avoid sensibilization 
to the allergenic animal proteins that accompanied the vaccine, the use of live animals for the growth of 
the different vaccines was substituted by tissue culture systems or embryonated chicken eggs. These 
second-generation vaccines are listed in Table 2. 
Lister was the first VACV strain used for the production of cell-cultured derived smallpox vaccines, being 
passaged in rabbit kidney cells, in the chorioallantoic membrane of chicken embryos (CE) or in primary 
cells derived from chicken embryos.  
Thus, the first second-generation Lister-based vaccine, RIVM, was produced in 1960 using rabbit 
kidney cells [51]. The virus was passaged directly from calf lymph vaccine to cells, and no further 
passages were performed for the generation of this vaccine. Freeze-dried vaccine demonstrated similar 
take rates and neutralizing antibodies to the calf lymph-derived vaccine [8]. This vaccine has been used 
in clinical trials in Netherlands and Indonesia without producing severe complications [52]. 
Table 2. List of the different second-generation VACV-based vaccines. 
Strain Vaccine Cell Culture References 
Lister 
RIVM Rabbit kidney cells [51] 
Israel Chorioallantoic membrane of CE [53,54] 
Lister/CEP CE cells [55] 
Elstree-BN CE cells [56,57] 
NYCBH 
CCSV MRC-5 cells [58] 
ACAM1000 MRC-5 cells [59] 
ACAM2000 VERO cells [60] 
CJ-50300 MRC-5 cells [61] 
WR Rabbits, mice, cell cultures  [43] 
Abbreviations: RIVM: Rabbit Lister Vaccine; CEP: Chicken embryo primary cells; CE: Chicken embryos; 
BN: Bavarian Nordic; CCSV: Cell Culture Smallpox Vaccine; WR: Western Reserve. 
Lister strain grown in chorioallantoic membranes of CE has been used in the military forces of Israel 
in the 1990s and 2000s with no severe complications observed [53,54]. Furthermore, Sanofi Pasteur 
developed another second-generation VACV vaccine, passaging a batch of the first-generation Lister vaccine 
during three passages in CE primary cells (CEP). This vaccine, Lister/CEP, was similar in immunogenicity 
and safety in comparison with the parental first-generation Lister vaccine [55]. In addition, Bavarian Nordic 
(BN) also manufactured a vaccine using Lister strain, called Elstree-BN, that was passaged in CE cells and 
demonstrated safety and immunogenicity in preclinical studies in monkeys [56] and in human clinical trials 
conducted in 2004 [57]. This vaccine was also prepared on chicken embryo fibroblast (CEF) cells in Japan 
before smallpox eradication and showed an adequate safety profile, but the effectiveness was not well 
documented [45]. 
Several second-generation VACV vaccines were also prepared using NYCBH as the seed strain. The 
first candidate was grown in cell cultures in 1968 and was used in clinical trials in the U.S. Army that 
had to be stopped due to the absence of adequate “take” rates observed [2]. Nonetheless, from that stock, 
another cell-cultured stock was developed in MRC-5 cells and received the name of Cell-Cultured 
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Smallpox Vaccine (CCSV). In 2002, a head-to-head phase I clinical trial comparison with Dryvax® was 
performed and dilutions up to 1/50 of CCSV vaccine showed a 100% take rate and no statistical significance 
differences in immunogenicity in comparison with Dryvax® [58]. Dryvax® was used to vaccinate military 
personnel in 2002 [62]. 
Another vaccine candidate derived from NYCBH is ACAM2000 (from Acambis), a vaccine derived 
from a clone isolated from Dryvax®. Originally six clones were isolated and their safety was evaluated 
in suckling mice and in rabbits. Significant differences in neurovirulence were observed among the 
different clones; CL2 is a clone with reduced neurovirulence that still maintains the same lesion size 
when compared with the Dryvax® vaccine [59]. This clone was selected and grown first in MRC-5 cells 
(ACAM1000) and, later on, in VERO cells generating the ACAM2000 vaccine [60]. Preclinical studies 
demonstrated that this strain was less neurovirulent in comparison with Dryvax®, but demonstrated 
similar immunogenicity in phase I clinical trials. Nonetheless, in phase II and III clinical trials, Dryvax® 
and ACAM2000 caused myocarditis associated with the vaccination [59,60]. The Food and Drug 
Administration (FDA) approved ACAM2000 in 2007 as a vaccine against smallpox for human use and 
Sanofi Pasteur manufactured the vaccine. 
NYCBH has also been used as a parental seed strain for the development of another second-generation 
VACV vaccine termed CJ-50300, which was obtained after passages in MRC-5 cells in South Korea. 
Compared to the first-generation Lancy-Vaxina vaccine, it showed similar reactogenicity, 
immunogenicity and neurovirulence in preclinical trials [47]. Moreover, a phase I clinical trial showed 
overall rates of 100% in cutaneous “take” reaction and humoral and cellular immunogenicity in CJ-50300 
vaccinees, with no serious adverse reactions being observed. However, one case of possible generalized 
vaccinia infection occurred in one of the studied groups [61].  
Other strains have been also derived from NYCBH such as Western Reserve (WR), a neurovirulent 
strain that has a wide history of passages; first in rabbits, followed in mice and in cell cultures [43],  
and Duke (isolated from a vaccinated patient that received Dryvax® vaccine [63]). As new research 
proves, VACV IHD-J, “International Health Department,” also shares a common ancestor with Dryvax®,  
i.e., NYCBH [28]. 
All these studies with second-generation vaccines demonstrate that although cell-cultured vaccines 
improved the control and the standardization that were lacking in previous vaccines, the use of 
replication-competent strains of VACV represents associated risks and serious adverse events that still 
have to be controlled.  
Several first- and second-generation poxvirus strains expressing different heterologous antigens have 
been used as vaccine candidates against a wide range of diseases. Table 3 summarizes the most relevant 
recombinant poxviruses used for these purposes. 
Other members of the poxvirus family have also been extensively used as vaccine vectors  
against homologous and heterologous diseases (see Tables 4 and 5). There are several examples of 
vaccines based on avipoxvirus, suipoxvirus, capripoxvirus, leporipoxvirus and parapoxvirus, which 
belong to the Chordopoxvirinae subfamily. 
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Table 3. Preclinical studies using first- and second-generation poxvirus strains as vaccine 
candidates against different viral, bacterial and parasitic infectious diseases. 
Poxvirus Strain Target Pathogen or Disease Heterologous Antigen Status References 
Lister 
Hepatitis B HBsAg preclinical [64,65] 
Cystic echinococcosis Echinococcus granulosus EG95 preclinical [66] 
Lassa Fever Nucleocapside preclinical [67] 
Wyeth 
Influenza A HA, NA, M1, M2 and NP from H5N1 preclinical [68,69] 
Hepatitis B preS2-S preclinical [70] 
Rinderpest F and HA preclinical [71] 
Lassa fever Glycoprotein preclinical [72] 
Anthrax PA of Bacillus anthracis preclinical [73] 
Copenhagen 
Rabies Glycoprotein preclinical [74,75] 
HCMV gB preclinical [76] 
RVHD Capsid protein (VP60) preclinical [77] 
Measles HA, F, NP preclinical [78] 
Equine Herpesvirus GP13 preclinical [79] 
WR 
Malaria PYCS, Pf155/RESA, GLURP preclinical [80–82] 
Influenza HA, NP preclinical [16,83] 
HIV/AIDS ENV, ENV (TAB13) preclinical [84–86] 
Leishmaniasis LACK preclinical [87,88] 
Hepatitis B HBsAg preclinical [89] 
Rabies Glycoprotein preclinical [74] 
Anthrax PA preclinical [90] 
Japanese Encephalitis Virus Structural proteins preclinical [91] 
Rinderpest F, HA preclinical [92,93] 
Measles F, HA preclinical [94] 
Brucella 18 kDa preclinical [95] 
Respiratory Sincitial Virus F, G preclinical [96] 
Feline Infectiuos Peritonitis Fusogenic Spike Protein preclinical [97] 
Abbreviations: HBsAg: Hepatitis B Virus Surface Antigen; HA: Hemagglutinin; NA: Neuraminidase;  
NP: Nucleoprotein; F: Fusion protein; PA: Protective antigen; HCMV: Human Cytomegalovirus;  
gB: Glycoprotein B; RVHD: Rabbit Viral Hemorrhagic Disease; ENV: Envelope; HBsAg: Hepatitis B Virus 
Surface Antigen; PYCS: Plasmodium Yoelii Circumsporozoite; GLURP: Glutamate Rich Protein;  
LACK: Leishmania homolog of activated C Kinase. 
Avipoxviruses (APVs) belong to the Chordopoxvirinae subfamily of the Poxviridae family. They infect 
and cause diseases in poultry, pets and wild birds, are transmitted via biting insects and aerosols and are 
usually named on the basis of the bird species from which the virus was first isolated and characterized [98]. 
APV infections have been reported to affect over 232 species in 23 orders of birds [99]. However, the 
knowledge of the molecular and biological properties of APVs is largely restricted to canarypox virus 
(CNPV) and fowlpox virus (FWPV), for which full genome sequences are available [100,101]. Despite 
the shorter FWPV genome, molecular comparisons show that CNPV and FWPV share 55–71% amino 
acid identity, significant gene-sequence rearrangements, deletions and insertions [101]. CNPV exhibits a 
broader tissue tropism in the permissive avian hosts than FWPV, generally associated with higher mortality 
rates [102]. Both viruses have been described as unable to replicate and disseminate infection in non-human 
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primates and humans [103], but some studies have shown replication of FWPV in non-permissive 
mammalian cell cultures by the presence of infectious viral particles [104] or the occasionalpresence  
of immature forms and mature intracellular virus in infected cells [105]. However, a recent study has 
demonstrated that despite the detection of mature virions in FWPV-infected VERO cells, the new progeny 
was not infectious [106]. Due to their natural host-range restriction to avian species [103,105,107],  
their efficient expression of heterologous genes also in human cells [108], and their ability to induce 
antigen-specific humoral and cellular immune responses [109,110], CNPV and FWPV represent alternative 
and safer vectors. In this context, several recombinant APVs have been evaluated as vaccine candidates 
against a wide range of infectious diseases and other APV-based vaccines have been licensed for commercial 
veterinary use against some animal infections; it is likely that such vaccines will also be used against 
human diseases in the future [111]. Table 4 summarizes the most relevant recombinant avipoxviruses used 
as vaccine vectors against different diseases. 
Table 4. Vaccine applications of avipoxvirus-based vectors. 
Pox Strain Target Pathogen or Disease Heterologous Antigen Status References 
Viral Infections 
CNPV HIV/AIDS HIV-1SF2 Env preclinical [112] 
FWPV 
HIV/AIDS 
HIV-1SF2 Env preclinical [112] 
SIVmac239 Gag/Pol, SIV89.6P Env, Gag/Pol, Env, Tat/Rev (clade B), 
Gag/Pol, Env, Tat/Rev (clade A/E), IFN-γ, IL-2 
preclinical [113–118] 
HIV-1 TAB9 multiepitopic polypeptide preclinical [119] 
MEG(4): multi-epitope gene (4 HIV-1 B cell epitopes), HIV-1 p24, 
MEG(25): multi-epitope gene (25 HIV-1 CTL epitopes) 
preclinical [120] 
HIVCN gp120, IL-2 preclinical [121] 
Gag, Env (clade D), cholera toxin B subunit preclinical [122] 
HIV-1SF2 Gag, Pol, HIV-1BH10 Env, IFN-γ preclinical [116,123] 
HIV-1SF2 Gag, Pol, IFN-γ clinical [124] 
Gag and Pol (clade B) clinical [125] 
Gag/Pol, Env, Tat/Rev (clade A/E) clinical [126] 
Env/Gag, Tat/Rev/Nef-RT (clade B) clinical [127] 
NDV F and HN 
licensed for commercial 
veterinary use (chickens) 
[128–136] 
ILTV gB (+AE) 
licensed for commercial 
veterinary use (chickens) 
[137–139] 
NDV + ILTV F and HN (NDV) + gB (ILTV) preclinical [128] 
IBV S1, S1 + IFN-γ, S1 + IL-18 preclinical [140–143] 
AEV AE (+LT) 
licensed for commercial 
veterinary use (chickens) 
[137] 
AIV 
native or synthetic HA, HA and/or NP, HA + IL-18 or IL-6, NA, 
HA + NA, LPAIV insert 
preclinical [144–161] 
IBDV VP2, VP2-VP4-VP3 preclinical [162–166] 
MDV glycoproteins B, E, I, H and UL32, pp38 preclinical [167–171] 
Rabies virus Glycoprotein preclinical [110,172] 
HPV L1 structural protein, E6 and E7 oncoproteins preclinical [173,174] 
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Table 4. Cont. 
Pox Strain Target Pathogen or Disease Heterologous Antigen Status References 
FWPV 
FMDV capsid and 3C protease, P1, 2A and 3C, IL-18 preclinical [175,176] 
CSFV E0 preclinical [177] 
DHBV DHBc and Pre-S/S antigens  preclinical [178] 
PRRSV GP5/GP3, IL-18 preclinical [179] 
TRTV F preclinical [180] 
CDV H and F antigens of RPV  preclinical [181] 
HEV native hexon  preclinical [182] 
MeV F preclinical [183] 
Smallpox VACV L1, A27, A33 and B5  preclinical [184,185] 
APV - preclinical [186–188] 
Bacterial diseases 
FWPV Mycoplasma gallisepticum 40 k and mgc gene segments  
licensed for commercial 
veterinary use (chickens) 
[189] 
Parasitic diseases 
FWPV Eimeria tenella rhomboid gene preclinical [190] 
Abbreviations: CNPV: Canarypox virus; FWPV: Fowlpox virus; NDV: Newcastle disease virus; ILTV: Infectious laryngotracheitis virus; 
IBV: Infectious bronchitis virus; AEV: Avian encephalomyelitis virus; AIV: Avian influenza virus; IBDV: Infectious bursal disease virus; 
MDV: Marek’s disease virus; HPV: Human papilloma virus; FMDV: Foot-and-mouth disease virus; CSFV: Classical swine fever virus; 
DHBV: Duck hepatitis B virus; PRRSV: Porcine reproductive and respiratory syndrome virus; TRTV: Turkey rhinotracheitisvirus;  
CDV: Canine distemper virus; RPV: Rinderpest virus; HEV: Hemorrhagic enteritis virus; MeV: Measles virus; F: Fusion protein;  
HN: Hemagglutinin-neuraminidase proteins; gB: Glycoprotein B; HA: Hemagglutinin; NP: Nucleoprotein; NA: Neuraminidase. 
Furthermore, other poxvirus vectors of the Chordopoxvirinae subfamily, such as the orthopoxvirus 
raccoon poxvirus, parapoxvirus, capripoxvirus, suipoxvirus and myxomavirus have been widely used as 
vaccine candidates against several animal and human diseases (see Table 5), showing good levels of 
safety and immunogenicity. 
Table 5. Preclinical studies using other pox vectors as vaccine candidates against different 
viral, bacterial and parasitic infectious diseases. 
Pox Strain Target Pathogen or Disease Heterologous Antigen Status References 
Raccoon 
poxvirus 
Influenza A HA and NA from H5N1 preclinical [191] 
Bubonic plague F1 capsular antigen of Yersinia pestis preclinical [192–196] 
Rabies 
Glycoprotein preclinical [19,197–200] 
Internal structural NP preclinical [198,201] 
Feline panleukopenia VP2 preclinical [199,202] 
FIPV Nucleocapsid preclinical [203] 
Parapoxvirus 
(orf) 
Influenza A HA or NP from H5N1 preclinical  [204] 
Rabies Glycoprotein preclinical  [205] 
PRV Glycoproteins gC and/or gD preclinical  [206–208] 
Borna disease NP p40 preclinical  [209] 
RVHD VP1 (VP60) preclinical  [210] 
CSFV E2 glycoprotein preclinical  [211] 
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Table 5. Cont. 
Pox Strain Target Pathogen or Disease Heterologous Antigen Status References 
Capripoxvirus 
PPRV F or HA preclinical  [212–218] 
HIV/AIDS 
HIV-1 subtype C Gag,  
reverse transcriptase, Tat and Nef 
preclinical [219,220] 
Rift Valley fever Glycoproteins Gn and Gc preclinical [221,222] 
Rinderpest F or HA preclinical [223–227] 
Bluetongue VP2, VP7, NS1 and NS3 preclinical  [228,229] 
Rabies Glycoprotein preclinical  [230] 
Suipoxvirus 
PCV2-associated disease  IL-18 + Cap, Cap preclinical  [231,232] 
SEZ 
M-like protein (SzP)  preclinical  [232] 
MRP of S. suis type 2 (SS2) preclinical  [233] 
Swine influenza 
HA1 from H3N2 and H1N1 preclinical  [234,235] 
HA1 from H3N2  preclinical  [236] 
HA1 from H1N1 preclinical  [236] 
Myxomavirus 
Bluetongue VP2 preclinical  [237] 
Feline calicivirus disease Cap preclinical  [238,239] 
Influenza  HA from H5N1 preclinical  [240,241] 
RVHD Capsid protein (VP60)  preclinical  [242–245] 
Abbreviations: HA: Hemagglutinin; NA: Neuraminidase; NP: Nucleoprotein; FIPV: Feline infectious peritonitis 
virus; F: Fusion protein; PCV2: Porcine circovirus type 2; Cap: Capsid protein; MRP: Muramidase-related 
protein; PRV: Pseudorabies virus; PPRV: Peste des petits ruminants virus; CSFV: Classical swine fever virus; 
SEV: Streptococcus equi ssp. Zooepidemicus; RVHD: Rabbit Viral Hemorrhagic Disease. 
5. Third-Generation VACV Vaccines: Evolution through Several Passages in Cultured Cells 
Given the unsatisfactory safety profile of VACV second-generation vaccines, attention has shifted to 
third-generation vaccines, obtained after serial passages in cell culture [37]. Thus, multiple extensive 
passages of a parental vaccine strain in cultured cells is a useful strategy for attenuating VACV through 
the generation of random mutations and deletions. Examples of this strategy are different VACV strains 
that are used as vaccine candidates, such as Lister clone 16m8 (LC16m8), Dairen I strain (DIs), M65 
and M101, Modified Vaccinia Virus Ankara (MVA) and several attenuated avipoxviruses. 
5.1. LC16m8 
LC16m8 was obtained in the late 1970s in Japan by passaging the parental Lister strain 36 times in 
primary rabbit kidney (PRK) epithelial cells at low temperature (30 °C), followed by isolation of one 
clone (LC16) that grows to the lowest titer in monkey kidney VERO cells; this was passaged six 
additional times in PRK cells to obtain the clone LC16m0 from the latter stock. Then, this clone was 
passaged three more times in PRK cells to generate the clone LC16m8 from the final stock [246,247]. 
LC16m8 replicates poorly in VERO cells, and formed small plaques in chick chorioallantoic membranes 
(CAM), PRK and RK13 cells. Thus, while LC16m8 can grow and produce infectious particles, it spreads 
poorly in cell culture. Compared to the original Lister strain, LC16m8 is temperature-restricted and 
displays limited host range, lower pathogenicity and adverse effects in animal models [247,248]. 
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LC16m8 contains a frame-shifting single nucleotide deletion in the B5R gene [30,249], which  
encodes an extracellular enveloped virus (EEV) protein (B5) essential for EEV formation. Analysis of 
the LC16m8 full-genome sequence showed that there are no large deletions compared to the parental 
Lister strain [30]. 
LC16m8 has been shown to induce protective immunity against orthopoxvirus challenge in  
mice [30,250,251], rabbits [250] and non-human primates [252,253]. Moreover, LC16m8 is a safe and 
immunogenic attenuated smallpox vaccine in immunodeficient mice [254] and vaccinia-naive  
humans [255,256]. However, there are two important main concerns about this vaccine. First, since the 
key attenuating mutation in B5R is a one base deletion that results in a frame-shift and early truncation 
of the B5 protein, the virus can revert back to wild type during growth [257]—although, to avoid this 
phenomenon, a new version of LC16m8, with a complete deletion in the B5R gene, has been generated [257]. 
The second concern is related to the fact that VACV B5 protein is the primary target antigen for 
generating neutralizing antibodies against EEV [258]. Thus, due to the presence of a mutation in B5R, 
LC16m8 failed to induce either EEV-neutralizing antibodies or antibodies to B5 in humans [259], a feature 
that may make LC16m8 a less efficient vaccine for protection against poxviruses. It remains to be seen 
whether this strain induces similar levels of neutralizing antibodies against VARV than other vaccine 
strains such as Dryvax®. 
Nevertheless, the combination of the deletion in the B5R gene (which causes the lack of anti-VACV 
vector immunity) with the insertion of heterologous antigens in the VACV TK or HA loci is a good strategy 
for using LC16m8 as a vaccine vector against infectious diseases. Thus, it has been reported that an 
attenuated recombinant LC16m8 expressing clade B HIV-1 Env [260] or SARS-CoV spike protein [261] 
was able to induce robust HIV-1-specific humoral and T cell immune responses or SARS-specific 
neutralizing antibodies in vaccinated mice and rabbits, respectively. 
Thus, LC16m8 is one of the safest live, attenuated, replication-competent vaccines; it is the  
sole smallpox vaccine licensed in Japan and was recently recommended by the WHO as one of the 
preferred WHO smallpox vaccines to stockpile. Furthermore, it is a promising vaccine vector against 
infectious diseases. 
5.2. Dairen I Strain (DIs) 
VACV DI strain was generated after 13 successive passages of parental Dairen strain in one-day-old 
eggs [262]. DIs forms small plaques in CAM, growing well only in chick embryo fibroblast (CEF) cells, 
but is unable to grow in most mammalian cells. DIs is a highly restrictive host range mutant that contains 
a great deletion of 15.4 Kb in the left terminal region of the VACV genome, which results in the loss of 
19 putative ORFs from genes C9L to K5L, including host-range genes K1L and C7L [263]. 
Insertion of HIV-1 Gag gene in the deleted region of DIs induced high levels of cytotoxic T lymphocytes 
in immunized mice [263]. Furthermore, a recombinant VACV DIs expressing simian immunodeficiency 
virus (SIV) Gag and Pol antigens induces SIV-specific cellular and humoral immuneresponsesin  
mice [264,265] or immunized non-human primates [266,267]. These results suggest that recombinant 
VACV DIs is a safe, efficient, transient replication-deficient viral vector, which can be used in a vaccine 
regimen for HIV-1 vaccine development. 
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5.3. M65 and M101 Virus 
M65 and M101 strains of VACV were generated in the 1980s after 65 and 101 passages, respectively, 
of Friend erythroleukemia (FEL) cell line persistently infected with WR strain [268]. During persistent 
infections of FEL cells, these mutants suffered large deletions of about 8 MDa at the left terminus of the viral 
genome [269] and alterations in some of the structural proteins with roles in the morphogenetic pathway, 
exhibit a small plaque size phenotype compared with WR parental virus, are highly attenuated and maintain 
replication capacity in some mammalian cell lines [270]. Their genomes have been recently sequenced, 
showing multiple point mutations and specific gene deletions [271]. Recombinants based on these and other 
mutants at early passages in FEL cells and expressing parasite antigens for malaria and leishmaniasis have 
been shown to elicit protection after challenge with parasites in prime/boost regimens in mice [268,271,272]. 
5.4. Modified Vaccinia Virus Ankara (MVA) 
MVA is a highly attenuated VACV strain generated in Germany in the 1960s by passaging the 
Turkish smallpox vaccine chorioallantoic VACV Ankara (CVA) strain more than 570 times in primary 
CEF cells [273,274]. During these extensive serial passages in cell culture, MVA lost nearly 15% 
(around 30 Kb) of the parental CVA genome (containing several point mutations and large deletions 
compared to CVA), mainly in both left and right terminal regions with many of the genes deleted 
involved in the host range and in the modulation of host immune responses [275,276]. As a result of this 
dramatic evolutionary genomic modification, MVA has lost the ability to produce infectious progeny virus 
in almost all mammalian cell lines, including human cells [274,276–278], replicating efficiently only in 
CEF and BHK-21 cells. Thus, in most of the cells MVA produces early, intermediate and late proteins, 
but only immature virions are formed [279]. Because of the inability to replicate in human cells, MVA 
would likely be safe to administer to people who have conditions that would not allow routine smallpox 
vaccination. In fact, MVA was used as a safe highly attenuated smallpox vaccine in the last decades of 
the smallpox eradication campaign (1968–1980), being inoculated into more than 120,000 people in 
Germany with no adverse side effects [274,280], although its efficacy against smallpox remains untested.  
Since then, MVA has been widely studied as a third-generation smallpox vaccine [281], able to induce 
antibody responses similar to Dryvax® [282] as well as protection in mouse [283] and non-human 
primate challenge models [56,284–286]. However, high doses or multiple doses of MVA have  
to be administrated to elicit immune protection, compared with other smallpox vaccines such as  
Dryvax® [283,287,288]. Nevertheless, this protection elicited by MVA is more rapid than the one 
induced by the fully replication-competent vaccine Dryvax® [286], mainly due to the induction of a more 
rapid immunity and an activation of the innate immune responses. Furthermore, MVA lacks several 
VACV immunomodulatory genes involved in evasion of the host immune responses, such as soluble 
receptors for type I and II IFNs, cytokines and chemokines [277,289], whose absence allows an enhanced 
antigen presentation and immunogenicity. In fact, deletion of innate immune evasion genes leads to an 
increase in proinflammatory cytokines and migration of immune cells [290–292], which have a great 
influence on their ability to elicit adaptive immunity. 
Thus, MVA has been evaluated as a smallpox vaccine in different animal models and several  
human clinical trials and was found to be safe and immunogenic without developing clinical  
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disease [2,283,285,287,293–300]. Although the MVA vaccine has not been tested directly in humans 
for efficacy against VARV, it has being tested against monkeypox triggering protection. In terms of 
MVA’s registration as a smallpox vaccine, the European Medicines Agency registered the vaccine as 
Imvanex and Health Canada also registered the vaccine for persons 18 years and older, while in the USA 
it is under evaluation by the FDA. 
Among poxviruses, MVA is the tip of the iceberg, being one of the most promising poxvirus vectors 
(reviews in [37,301–310]). Enormous effort has been put into the use of MVA as a vaccine vector, with 
several preclinical and human clinical trials developed using MVA as a vaccine candidate against an 
extensive number of infectious diseases, such as HIV/AIDS, malaria, tuberculosis, hepatitis C and 
cancer, among many others. Table 6 summarizes the use of MVA in preclinical and human clinical trials 
as a vaccine candidate against different viral, bacterial and parasitic infectious diseases. 
Table 6. Preclinical and clinical trials using MVA vector as a vaccine candidate against 
different viral, bacterial and parasitic infectious diseases. 
Target Pathogen or Disease Heterologous Antigen Status References 
Viral diseases 
Variola (smallpox) Whole MVA vector clinical [299,300,311] 
HIV/AIDS 
HIV-1 Gag p24 and p17 fused to 25 overlapping CTL CD8 T cell epitopes 
(clade A) 
clinical [312] 
HIV-1 Env (clade E); Gag-Pol (clade A) clinical [313] 
HIV-1 Env, Gag, Tat-Rev and Nef-RT (clade C) clinical [314] 
HIV-1 Env, Gag-Pol, Nef-Tat (clades B/C) clinical [315] 
HIV-1 Gag, PR, RT, Env (clade B) clinical [316] 
HIV-1 Env/Gag, Tat/Rev/Nef-RT (clade B) clinical [127] 
HIV-1 Env, Gag-Pol-Nef (clade B) clinical [305] 
21 CTL and 18 HTL epitopes from HIV-1 Gag, Pol, Vpr, Nef, Rev and Env clinical [317] 
HIV-1 Nef clinical [318] 
Influenza A 
NP+M1 clinical [319] 
HA from H5N1 clinical [320] 
Hepatitis B 
HBs clinical [321] 
30 CTL and 16 HTL epitopes preclinical  [322] 
Hepatitis C 
NS3, NS4 and NS5B (genotype 1b) preclinical and clinical [323,324] 
E1 and E2 (genotype 1b) preclinical  [325] 
C, E1 and E2, p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B (genotype 1a) preclinical  [326] 
Chikungunya 
C, E3, E2, 6K and E1 preclinical  [327] 
E3 and E2 preclinical  [328] 
E3-E2, 6K-E1 or E3-E2-6K-E1 preclinical  [329] 
Dengue 
Envelope (Dengue type 2 virus) preclinical [330] 
Envelope (Dengue type 3 virus) preclinical  [331] 
Ebola GP (Zaire and Sudan strains) preclinical [332] 
CCHF GP preclinical  [333] 
SARS 
Spike protein preclinical  [334–337] 
Spike or nucleocapsid proteins preclinical  [338] 
Nucleocapsid preclinical  [339] 
MERS Spike protein preclinical  [340] 
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Table 6. Cont. 
Target Pathogen or Disease Heterologous Antigen Status References 
Viral diseases 
FIPV Membrane protein preclinical  [341] 
RSV F or G glycoprotein preclinical [342–344] 
Rift valley fever Gn/Gc GP preclinical  [345,346] 
Rabies Glycoprotein preclinical  [347] 
JEV 
Membrane (prM) and envelope (E) proteins (Korean strain) preclinical  [348–350] 
B cell, CTL and Th multiple linear epitopes (SA14 strain) preclinical  [351] 
Measles 
HA preclinical  [352] 
F and HA preclinical [94,353] 
CMV 
Soluble GP B (gB) preclinical  [354] 
UL55 (surface glycoprotein), UL83 (tegument protein) and UL123/e4 (nuclear 
protein) 
preclinical  [355] 
pp65 (tegument protein) and CMV immediate early gene IE1 preclinical  [356] 
pp65-2, gB and IE1 (Rhesus CMV) preclinical [357,358] 
pp65, IE1, IE2 preclinical  [359] 
pp65 preclinical [360] 
glycoproteins gH/gL, UL128, UL130 and UL131A (UL128C) preclinical [361] 
gH, gL, UL128, UL130 and UL131A preclinical  [362] 
BoHV-1 Secreted GP D preclinical  [363] 
EHV-1 Complement-receptor GP C preclinical [364] 
HSV GP D (gD) (HSV-2) preclinical  [365] 
Parainfluenza virus F and/or HN glycoproteins (parainfluenza virus 3) preclinical [366–368] 
Bacterial diseases 
Tuberculosis Mycobacterial mycolyl-transferase antigen 85A clinical [369–371] 
Babesia bovis  MSA-2c, RAP-1 and HSP20 proteins preclinical  [372] 
Bubonic plague Yersinia pestis low-calcium response V antigen preclinical  [373] 
Parasitic diseases 
Malaria 
ME-TRAP clinical [374,375] 
AMA1 clinical [376–380] 
MSP1 clinical [377–379,381] 
CS clinical [375,382] 
Polyprotein consisting of six pre-erythrocytic antigens from P. falciparum clinical [383] 
Leishmaniasis 
LACK preclinical  [88,271,384–386] 
TRYP (Leishmania major substrain LV39) preclinical  [387] 
TRYP (Leishmania infantum) preclinical  [388] 
TRYP (Leishmania (Viannia) panamensis) preclinical  [389] 
Toxoplasmosis ROP2 preclinical  [390] 
Chagas disease Trypanosoma cruzi TcG2 and TcG4 preclinical  [391] 
Abbreviations: CTL: Cytotoxic T cell; HTL: Helper T lymphocyte; NP: Nucleoprotein; M1: Matrix protein 1; HA: Hemagglutinin; HBs: 
Hepatitis B surface antigen; GP: Glycoprotein; NHP: Non-human primates; CCHF: Crimean-Congo hemorrhagic fever; SARS: Severe acute 
respiratory syndrome; MERS: Middle East Respiratory Syndrome; FIPV: Feline infectious peritonitis virus; RSV: Respiratory syncytial virus; 
F: Fusion protein; JEV: Japanese encephalitis virus; CMV: Cytomegalovirus; BoHV-1: Bovine herpesvirus-1; EHV-1: Equine herpesvirus 
type 1; HSV: Herpes simplex virus; HN: Hemagglutinin-neuraminidase; ME-TRAP: Multiple epitope-thrombospondin-related adhesion 
protein; AMA1: P. falciparum blood-stage malaria antigen apical membrane antigen 1; MSP1: P. falciparum blood-stage malaria antigen 
merozoite surface protein 1; CS: Circumsporozoite protein; LACK: Leishmania homologue of receptors for activated C kinase; TRYP: 
Tryparedoxin peroxidase; ROP2: Toxoplasma gondii rhoptry protein 2. 
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5.5. Attenuated Avipoxviruses 
Similar to VACV-derived strains, when considering the development of an APV-derived vector for 
production of a vaccine for birds, the use of an attenuated strain is recommended to reduce the risk and 
consequences of environmental spread to other avian species. Attenuated derivatives of FWPV (such as 
TROVAC or FP9) and CNPV (such as ALVAC) have been extensively tested, demonstrating their safety 
in a variety of species, including immunocompromised animals and human volunteers. Despite the fact 
that their multiplication is restricted to avian species, attenuated strains of APVs have been demonstrated 
to be efficacious and extremely safe vectors for mammals. Indeed, it was discovered that inoculation of 
APV-based recombinants into mammalian cells resulted in expression of the foreign gene and that 
inoculation into mammals resulted in the induction of protective immunity [103,172] (see Table 7). 
Table 7. Vaccine applications of attenuated avipoxvirus-based vectors.  




licensed for commercial 
veterinary use (chickens) 
[153,405–408] 
NDV F and HN preclinical [409] 
ALVAC 
HIV/AIDS 
SIVK6W Gag-Pol-Env, Gag-Pol preclinical [118,410] 
HIV-1IIIB Env preclinical [411] 
HIV-1MN gp160 clinical [412–416] 
HIV-1MN gp120 linked to TM domain of HIV-1LAI 
gp41, HIV-1LAI Gag and protease 
clinical [417–424] 
HIV-1MN gp120 linked to TM domain of HIV-1IIIB gp41, 
HIV-1IIIB Gag and protease, 3 CTL-dense regions of 
HIV-1LAI pol, 2 CTL-dense regions of HIV-1LAI nef 
clinical [425] 
CRF01_AE gp120 (92TH023) linked to TM domain 
of HIV-1LAI gp41, HIV-1LAI Gag and protease 
clinical [404,426–432] 
CMV 
gB clinical [433,434] 
pp65  clinical [435] 
Rabies virus Glycoprotein 
licensed for commercial 
veterinary use (cats) 
[436] 
clinical [437,438] 
CDV HA and F 
licensed for commercial 
veterinary use (dogs, ferrets) 
[439–442] 
West-Nile virus PrM-E 
licensed for commercial 
veterinary use (horses) 
[443–447] 
FeLV 
Env, Gag preclinical [448] 
Env, Gag/pol 
licensed for commercial 
veterinary use (cats) 
[448–450] 
FIV FIV Ville Franche (subtype A) Env, Gag and Protease preclinical [451] 
EIV HA 
licensed for commercial 
veterinary use (horses) 
[452–454] 
EHV gB, gC and gD preclinical [455] 
JEV prM, E, NS1 clinical [456,457] 
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Table 7. Cont. 
Poxvirus Strain Target Pathogen or Disease Heterologous Antigen Status References 
ALVAC 
HTLV-1 Env preclinical [458] 
AHSV VP2 and VP5 preclinical [459,460] 
RHDV capsid protein preclinical [461] 
HCV capsid, E1, E2, NS2, NS3 preclinical [462] 
BTV VP2 and VP5 preclinical [463] 
AIV HA preclinical [408,464] 
Bacterial diseases 
FP9 Tuberculosis Ag85A preclinical [465] 
Parasitic diseases 
FP9 Malaria 
CS preclinical [466] 
L3SEPTL (six-linked pre-erythrocytic antigens) preclinical [467] 
ME-TRAP, CS clinical [468–474] 
ALVAC Malaria 
CS, SSP2, LSA1, MSP1, SERA, AMA1, Pfs25 CS, 
SSP2, AMA1, MSP1 
preclinical [475,476] 
Abbreviations: AIV: Avian influenza virus; NDV: Newcastle disease virus; CMV: Cytomegalovirus; CDV: Canine distemper virus;  
FeLV: Feline leukemia virus; FIV: Feline immunodeficiency virus; EIV: Equine influenza virus; EHV: Equine herpes virus; JEV: Japanese 
encephalitis virus; HTLV-1: Human T cell leukemia/lymphoma virus type 1; AHSV: African horse sickness virus; RHDV: Rabbit hemorrhagic 
disease virus; HCV: Hepatitis C virus; BTV: Bluetongue virus; F: Fusion protein; HN: Hemagglutinin-neuraminidase proteins; HA: 
Hemagglutinin; TM: Transmembrane; gB: Glycoprotein B; pp65: Phosphoprotein 65; CS: Circumsporozoite protein; ME-TRAP: Multiple 
epitope-thrombospondin-related adhesion protein; SSP2: Sporozoite surface protein 2; LSA-1: Liver stage antigen 1; MSP1: Merozoite 
surface protein 1; SERA: Serine repeat antigen; AMA1: Apical merozoite antigen 1.  
5.5.1. TROVAC 
For the generation of TROVAC, the attenuated fowlpox vaccine strain FP-1 [103], derived from the 
Duvette strain, was subjected to four successive plaque purifications. Then, one plaque isolate was 
further amplified in primary CEF cells and a viral stock, designated as TROVAC, was generated and 
deposited with the American Type Culture Collection (ATCC; Accession number: VR-2553) [392]. 
5.5.2. FP9 
FP9 is a highly attenuated form of FWPV derived from the wild-type fowlpox virus HP-1 by  
438 serial passages in CEF cells [393]. The FP9 genome has been fully sequenced and found to harbor 
several deletions/insertions and gene modifications when compared with the sequence of wild-type 
FWPV strains [394]. 
5.5.3. ALVAC 
ALVAC is a plaque-purified clone derived from an attenuated CNPV obtained from the wild-type 
strain after 200 serial passages in CEF cells [395]. It has been extensively evaluated in preclinical studies 
with non-human primates [396–400], widely used in human clinical trials as an HIV/AIDS vaccine 
candidate [109,401], and licensed for veterinary use [111]. ALVAC-based vectors have been reported 
to be well tolerated and safe for humans [402,403] and the first sign of efficacy of an HIV/AIDS vaccine 
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candidate, although modest (31.2%), was obtained in a phase III clinical trial using an ALVAC-based 
vector [404]. 
6. Fourth-Generation VACV Vaccines: Evolution through Genetic Engineering 
The innovative biotechnology techniques of genetic engineering that have been developed in the 
1980s and 90s allow the generation of novel poxvirus vaccines through the insertion or deletion of 
specific genes in the poxvirus genome. In 1982, two independent groups showed for the first time that 
VACV can be modified to be used as an expression vector system, where foreign DNA can be inserted 
into non-essential regions of the VACV genome [13,14]. Since then several recombinant poxviruses 
have been generated and used as effective vector systems for vaccination-expressing heterologous 
antigens that were able to induce strong antigen-specific cellular and humoral responses, reinforcing the use 
of recombinant poxviruses as vaccine candidates against a broad range of infectious diseases. Numerous 
replication-deficient and competent poxvirus-based vectors have been widely and successfully used as 
vaccine candidates in preclinical and clinical trials in the prevention and treatment of different animal 
and human diseases (reviews in [37,301–310,477–480]). The genetic modifications normally attenuated 
the virus and led to an increase in immunogenicity against the VACV antigens or against the heterologous 
antigens expressed from the poxvirus vector. 
6.1. Deletion of Genes 
Poxviruses encode for many proteins involved in the host innate immune evasion, with secreted 
proteins that bind and neutralize IFNs, cytokines and chemokines, or intracellular proteins that inhibit 
apoptosis or signaling pathways that lead to the production of IFNs or proinflammatory cytokines and 
chemokines [289]. Thus, deletion of these VACV genes involved in immune-modulation, host-range and 
accessory nucleotide metabolism genes is one of the techniques that has been widely used to generate 
novel poxvirus vectors with a more attenuated profile or novel vaccine candidates with optimized 
immunogenicity [481].  
One of the best examples of an attenuated VACV vector generated by the deletion of viral genes  
is NYVAC, a VACV strain derived from a plaque-cloned isolate (VC-2) of the Copenhagen strain 
(VACV-COP) by the precise deletion of 18 Open Reading Frames (ORFs). These deleted genes include 
12 ORFs from C7L to K1L genes, J2R (TK), B13R, B14R, A26L, A56R (HA) and I4L and are involved in 
pathogenicity, virulence and host-range functions [482]. The resultant vector exhibits a dramatically 
reduced ability to replicate on a variety of human and mammalian cell types, is highly attenuated since it fails 
to disseminate in immunodeficient mice, and is unable to produce infectious virus in humans [482–484]. 
Despite its limited replication in human and most mammalian cells, NYVAC provides a high level of gene 
expression and triggers antigen-specific immune responses when delivering foreign proteins in animals 
and humans [485–488]. For this reason, NYVAC-based recombinants are underintensepreclinical  
and clinical investigation as recombinant vaccines against multiple infectious diseases [305,306,483]  
(see Table 8). 
  
Viruses 2015, 7 1745 
 
 
Table 8. Vaccine applications of fourth-generation poxvirus-based vectors generated by the 
deletion of poxviral genes. 




Glycoprotein, gB or gD glycoproteins,  
gII, gIII and/or gp50 glycoproteins 
preclinical [483,489–494] 
CDV F and HA  preclinical [440–442] 
EHV gene 64 preclinical [455] 
JEV prM, E, NS1 clinical [456,457] 
HIV/AIDS 
SIVK6W Env-Gag-Pol, SHIV89.6P Env,  
SIVmac239 Gag-Pol-Nef 
preclinical [487,495–497] 
Env (clade B) preclinical [411] 
clade C trimeric soluble gp140(ZM96),  
clade C Gag(ZM96)-Pol-Nef(CN54) as VLPs 
preclinical [498] 
Env, Gag-Pol-Nef (clade C) clinical [499–503] 
Env, Gag-Pol-Nef (clade B) clinical [504,505] 
AIV HA preclinical [408] 
HTLV-1 Env, Env + Gag preclinical [458,506,507] 
Parasitic diseases 
NYVAC Malaria 
LSA-1, CS preclinical [508] 
CS, SSP2, LSA1, MSP1, SERA, AMA1, Pfs25 clinical [509] 
Abbreviations: PRV: Pseudorabies virus; AIV: Avian influenza virus; CDV: Canine distemper virus;  
EHV: Equine herpes virus; JEV: Japanese encephalitis virus; HTLV-1: Human T cell leukemia/lymphoma 
virus type 1; F: Fusion protein; HA: Hemagglutinin; CS: Circumsporozoite protein; SSP2: Sporozoite surface 
protein 2; LSA-1: Liver stage antigen 1; MSP1: Merozoite surface protein 1; SERA: Serine repeat antigen; 
AMA1: Apical merozoite antigen 1. 
Most of the studies involved in the deletion of immune-modulating VACV genes have been performed 
in the VACV WR strain and the general results showed that deletion of many VACV genes attenuated the 
virus [289], but the impact on immunogenicity was variable. Thus, deletion of some immunomodulatory 
VACV genes from different strains (mainly WR and MVA) increased the immunogenicity against VACV 
antigens, as it is described for VACV genes E3L [510], B15R/B16R [511–513], A41L [514], B13R  
and B22R [515], C12L [516], A35R [517] or C6L [518]. However, deletion of other immunomodulatory 
genes has no effect on the virulence or pathogenicity, as in B8R [519,520], or does not enhance the 
immunogenicity against VACV, as in N2L [521] or C16L [522]. Moreover, deletions of C12L, A44L, A46R 
or B7R in MVA did not significantly affect VACV-specific CD8 T cell immunogenicity in BALB/c  
mice [511]. Furthermore, the Wyeth strain with deletions of coding regions for the B5R, B8R, B12R, B13R, 
B14R, B16R, B18R and B19R immunomodulatory gene products did not increase the immunogenicity of 
these vectors compared with the parental VACV [523]. 
Recently, several deletions in the Tian Tan strain have been performed and analyzed. For example, a 
recombinant Tian Tan VACV expressing HIV-1 Gag, Pol and Env genes and with deletions in the C12L 
and A53R genes is highly attenuated and retains the high immunogenicity of the parental virus to elicit 
strong humoral and cellular responses to the HIV-1 target genes [524]. 
In addition, it has been reported that deletion in the Lister strain of the five major nonessential regions 
that are deleted in MVA enhances the attenuation, although the VACV-specific immune responses were 
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similar to those of the traditional smallpox vaccine [525]. Nonetheless, introduction of the six major 
genomic deletions of MVA into the parental VACV CVA is not sufficient to reproduce an MVA-like 
phenotype in cell culture and in mice [526]. 
Combination of the insertion of a heterologous antigen in a poxvirus vector with the deletion of  
an immunomodulatory VACV gene is a promising novel approach to optimize the poxvirus vaccine  
vector by enhancing immunogenicity against the foreign antigen [481]. This strategy has been  
widely used for the generation of optimized recombinant MVA and NYVAC vectors expressing HIV-1 
antigens (which are used as HIV/AIDS vaccine candidates) and containing single or multiple deletions 
in immunomodulatory VACV genes that antagonize host-specific immune responses. These new 
optimized recombinant MVA and NYVAC vaccine vectors lacking VACV immunomodulatory genes 
have been tested in mice [327,516,527–532] and non-human primates [533,534], and the overall results 
showed that they induced an enhancement in the HIV-1-specific cellular and humoral immune responses. 
Thus, the removal of VACV immunomodulatory genes that block the host immune responses to the 
infection is a useful method to enhance the antigen-specific immune responses induced by different 
poxvirus-based vaccine candidates. Dissection of the immune profile induced by these novel poxvirus 
vectors with deletions in single genes or in gene families is necessary to find an optimized poxvirus 
vector that could enter into future human clinical trials to test whether it can provide protection against 
infection. In fact, system biology profiles of NYVAC vectors expressing HIV-1 antigens and lacking 
the IFN inhibitors B8 and B19 revealed in human macrophages distinct gene signatures that can be 
correlated with immune parameters relevant in protection [535]. Gene signatures have also been defined 
for the HIV vaccine candidates MVA-B [291] and MVA-C [536]. A summary of poxvirus genes deleted 
in the context of poxvirus-based vaccine vectors against different infectious diseases is shown in Table 9. 
Table 9. Poxvirus genes deleted in poxvirus-based vaccine candidates against infectious 








Gene Function Status References 
MVA HIV/AIDS 
HIV-1 Env,  
Gag-Pol-Nef (clade B) 
A41L/B16R 
A41L: Secreted chemokine-binding protein  
B16R: Secreted interleukin-1β binding protein 
preclinical [528] 
HIV-1 Env,  
Gag-Pol-Nef (clade B) 
C6L  IRF3 inhibitor preclinical [527,529] 
HIV-1 Env,  
Gag-Pol-Nef (clade B) 
C6L/K7R 
C6L: IRF3 inhibitor  
K7R: NF-кB/IRF3 inhibitor 
preclinical [527] 
HIV-1 Env,  
Gag-Pol-Nef (clade B) 
N2L IRF3 inhibitor preclinical [537] 
HIV-1 Env,  
Gag-Pol-Nef (clade C) 
F1L Anti-apoptotic protein preclinical [532] 
HIV-1 Env,  
Gag-Pol-Nef (clade C) 
C12L IL-18 binding protein preclinical [516] 
HIV-1 Env,  
Gag (clade C) 
C12L/A46R/B7R
/B16R 
C12L: IL-18 binding protein  
A46R: Inhibitor of TLR signaling  
B7R: Putative chemokine-binding protein  
B16R: Secreted interleukin-1β binding protein 
preclinical [533] 
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Gene Function Status References 
NYVAC HIV/AIDS 
HIV-1 Env,  
Gag-Pol-Nef (clade C) 
B8R  Secreted IFNγ binding protein preclinical [530] 
HIV-1 Env,  
Gag-Pol-Nef (clade C) 
B19R  Type I IFN binding protein preclinical [530] 
HIV-1 Env,  
Gag-Pol-Nef (clade C) 
A46R Inhibitor of TLR signaling preclinical [531] 
MVA Chikungunya C-E1-E2-6K-E3 C6L/K7R/A46R 
C6L: IRF3 inhibitor  
K7R: NF-кB/IRF3 inhibitor  
A46R: Inhibitor of TLR signaling 
preclinical [327] 
MVA Smallpox - A35R Inhibitor of MHC class II antigen presentation preclinical [517] 
MVA Smallpox - A41L  Secreted chemokine-binding protein. preclinical [514] 
MVA Smallpox - C6L IRF3 inhibitor preclinical [518] 
MVA Smallpox - B16R Interleukin-1β binding protein preclinical [511–513] 
NYCBH Smallpox - E3L dsRNA-binding protein  [538–540] 
FWPV AIV HA 
ORF73 or 
ORF214 
Suggested interleukin-18 binding proteins preclinical [541] 
Abbreviations: AIV: Avian influenza virus; HA: Hemagglutinin. 
6.2. Insertion of Genes 
One of the advantages of replication-deficient viruses is their safety profile. However, it has been 
postulated that the efficacy of these viruses is restricted due to the failure to replicate and the limitation 
in antigen accumulation during virus infection. For this reason, the restoration of replication competence 
in human cells, together or not with the deletion of specific immunomodulatory VACV genes, can be a 
strategy to improve the efficacy of poxvirus-based vectors. 
In the case of the NYVAC vector, the restoration of replication capacity is obtained by the reinsertion 
of K1L and/or C7L host range genes in the viral genome. It has been reported that these new constructs 
are still attenuated but acquire new biological properties distinct from the parental NYVAC that make 
them potentially improved vaccine vector candidates for human applications [542,543] (see Table 10). 
Furthermore, the gene signatures of a replication-competent NYVAC vector expressing HIV-1 genes 
(termed NYVAC-C-KC) in human dendritic cells have been described [542]. 
Another category of genes that has been used to improve poxviruses as vaccine vectors is those  
that encode co-stimulatory molecules such as IL-1α, IL-2, IFN-γ, IL-12, IL-15, OX40/OX40L, B7-1, 
ICAM-1, LFA-3, CD80, CD86, CD83, CD40L or GM-CSF [481]. This strategy significantly enhanced 
the immunogenicity and efficacy of the poxvirus vector as a vaccine against different infectious diseases 
and has been extensively used against cancer (see Section 7). However, there is a limitation on the insertion 
of this immunomodulators. Ramshaw and colleagues discovered in 2001 that the insertion of mouse 
interleukin-4 by a recombinant ectromelia virus suppressed antiviral cell-mediated immune responses [544]. 
This has been further explored and the insertion of this Th2 cytokine into several poxviruses significantly 
increased the efficiency of the recombinant virus as a pathogen by directly inhibiting the development 
of Th1 immunity, which is crucial for viral clearance [545,546]. 
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Table 10. Vaccine applications of fourth-generation poxvirus-based vectors generated by the 












HIV-1 Env, Gag-Pol-Nef (clade C) 
VACV K1L and C7L 
(B19R deletion) 
Host range preclinical [542,543] 
HIV-1 Env, Gag-Pol-Nef (clade B) VACV C7L  Host range preclinical [547] 
MeV HA VACV K1L Host range preclinical [548] 
ALVAC HIV/AIDS 
HIV-1MN gp120 linked to TM domain of 
HIV-1LAI gp41, HIV-1LAI Gag and protease, 
synthetic polypeptide encompassing several 
human nef and pol epitopes, CD40L 






NYVAC Malaria CS VACV K1L Host range preclinical [557] 
Abbreviations: MeV: Measles virus; HA: Hemagglutinin; TM: Transmembrane; PKR: Double-stranded RNA-dependent protein kinase; 
2'5'OAS: 2'-5' oligoadenylate synthetase; CS: Circumsporozoite protein. 
6.3. Gene Expression Optimization 
The optimization of gene expression of poxvirus-based vaccines is addressed to improve the 
generation of immune responses to the heterologous antigen. Thus, the regulation of the antigen 
expression level is an alternative vaccine-design strategy adopted to induce antigen-specific immune 
responses [558]. 
In this regard, the late-early VACV p7.5 promoter [559] was the first strategy used to induce 
heterologous antigen expression. The removal of poxvirus transcription termination signals from 
inserted genes [560] and the regulation of gene expression under the bacteriophage T7 promoter [561], 
the vaccinia modified H5 (mH5) [366] and the vaccinia short synthetic early-late pS [562] promoters 
have been used as alternatives to p7.5 to increase the quantity of heterologous antigen expressed  
during infection. 
Recently, it has been demonstrated that the efficiency with which an antigen is processed and presented 
on the surface of infected cells influences its recognition [563]. In fact, in VACV, 90% of the antigens 
most recognized by CD8 T cells were ranked among the top 50% in terms of mRNA expression [564], 
and there is a correlation between the timing of viral antigen expression and the generation of antigen-specific 
immune responses [565]. For this reason, efforts towards developing new poxvirus vaccines candidates are 
focused on using promoters to improve the timing rather than the quantity of antigen expression. 
After a deep analysis of the VACV transcriptome, two groups have defined two categories of early  
genes based on their temporal expression [566,567]. Based on these studies, endogenous poxviral early 
promoters have been compared with the p7.5 and pS promoters. The pC11R and pF11L promoters 
induced high levels of early antigen expression and cellular immunogenicity similar to those of p7.5 and 
pS promoters [568]. 
More recent studies demonstrate that it is possible to design poxvirus promoters that improve early 
antigen expression and antigen-specific T cell responses. In this regard, synthetic early promoters such 
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as psFJ1-10 [569,570] or pHyb [571] and native early promoters like PrMVA13.5-long [572] present 
repeated motifs, each containing an early promoter element. An alternative strategy for poxvirus promoter 
design is the optimization of the early promoter element after bioinformatic analysis, as indicated by the 
Late-Early Optimized (LEO) promoter [573]. These new promoters are able to increase the expression of 
heterologous antigens and their specific immune response compared to the p7.5 and pS. They represent 
excellent prototypes for the generation of safe poxvirus recombinant-based vaccines to potentiate the 
antigen expression and immune response. 
7. Poxvirus Evolution as Vaccines to Fight Cancer 
Poxviruses represent strong contenders for cancer vaccine development given their ability to express 
large foreign genes, capacity to induce a strong cytotoxic T lymphocyte (CTL) responses, broad tissue 
tropism, fast replication and lysis of infected cells, potential to take advantage of the tumor 
microenvironment (deregulation of cell cycle control, partially blocked IFN response and apoptosis or 
immune evasion), and the absence of DNA integration into the host genome for safety [574].  
All these features could be a potential solution to a range of issues that characterize cancer: low 
immune response generated by tumor-associated antigens (TAA), strong immune-suppressor tumor 
environment, antiviral immune response elicited by the vector and concerns regarding the safety of the 
vaccine used (sites of virus infection and/or replication, toxicity of the transgene expressed, or other 
vaccine-associated side effects) [575,576]. 
In 1963, for the first time, a poxvirus was assayed as a potential vector to treat tumors; in this case, 
Purified Vaccine Lymph was used to treat various skin cancers by local injection [577]. Within the 
several poxvirus-based strategies deployed and analyzed at preclinical stages for cancer vaccine 
development, VACV, FWPV, CNPV and their combinations as vectors represent the majority seen on 
Table 11. 
As we have described for infectious diseases, in the development of different vaccines against cancer, 
various approaches involve the insertion of heterologous genes into common poxvirus strains, such as 
immunotherapy by the expression of TAA (e.g., MUC1 [578], oncofetal antigen 5T4 [579], PSA [580], 
CEA [581]), the expression of immunomodulatory genes (e.g., costimulatory molecules-B7.1,  
B7.2 [582], CD80 [583] or cytokines-IL-2 [584], IFN-β [585], GM-CSF [586]), the expression of suicide 
genes (e.g., cytosine deaminase [587], purine nucleoside phosphorylase [588]), and the expression of 
genes used for the imaging as a support for combination therapies (thyroidal sodium iodide symporter 
NIS [589]). 
On the other hand, a different artificial evolution of poxviruses has been performed to direct the 
natural oncolytic capacity of this family, generating tumor-tailored viruses that grow to a higher extent 
in tumor cells and microenvironment. In this way, poxviruses have been engineered by the deletion of 
specific genes involved in nucleotide metabolism, interferon response, the cell cycle and other cell 
functions abnormally regulated in tumor cells (e.g., J2R, C11R, B18R [574]).  
Likewise, combinations of all the different strategies mentioned above have been evaluated altogether 
in different immunization protocols. Some of these strategies are especially promising, which is reflected 
in the significant number of human clinical trials in phase I, II or III that have been or are being carried 
out targeting different types of cancers such as melanoma, breast, prostate or liver cancer [479]. 




Table 11. Poxvirus-based vaccine candidates against cancer. 
Poxvirus Strategy Strain Gene Status References 
Vaccinia virus 
TAA MVA, Copenhagen 
Deletion: J2R, A56R, IGR3 
preclinical [578–580,590–600] 
Neu oncogene; MUC1; oncofetal antigen 5T4; tumor-associated 
auto-antigen p53; PSA; PSCA; STEAP1; GA733 Ag; AFP; 
murine surviving; HPV-16 E1 oncoprotein; EBNA1-LMP2 






MVA, WR, Copenhagen 
Deletion: J2R, A56R, I4L, A44L 
preclinical [479,582–584,606,607] 
TAA: MUC1, Melan-A/Mart-1 27-15 minigene; gp100280–288 + 
Melan-A/MART-127–35 + tyrosinase1–9 tumor-associated antigen 
epitopes; HER-2 
IL-2; costimulatory molecules B7.1 and B7.2; CD80 and CD86; 
p2 and p30 T helper cell epitopes from tetanus toxin 
Oncolysis 
WR, Copenhagen, Wyeth, 
MVA, Lister, LIVP 
Deletion: J2R, C11R, B18R, F14.5L Mutation: A34L, A5L 
preclinical [581,587–589,608–615] 
hNIS; CEA; Neu oncogene; ETA; polyomavirus-specific  
tumor-specific antigens; early bovine papillomavirus proteins; 




Genes: J2R, C11R, B18R, A56R 
preclinical [479,585,616–626] 
VEGF-binding ectodomain from Flk1; T-cell engager  
EphA2-TEA; GM-CSF; IFN-β; CCL5 (RANTES); IL-2; IL-12 
(p35 and p40 subunits); FasL; CXCR4; CD40L 
Fowlpox virus 















TAA: CEA; gp100 protein 
preclinical [479,631–635] 
costimulatory molecule B7.1 
Immunomodulation Myxoma Fusion Protein of Interleukin-15 (IL15) and IL15 Receptor Alpha preclinical [636] 
Oncolysis Myxoma Gene insertion: VACV F11L preclinical [637,638] 
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Table 11. Cont. 
Poxvirus Strategy Strain Gene Status References 
Mix 










TAA: PSA; CEA; MUC1 
preclinical [479,643–649] 
TRICOM; GM-CSF; IL-2 
Parapox virus Oncolysis NZ2 vascular endothelial growth factor locus preclinical [650] 
Raccoonpox virus Oncolysis Not described GFP (TK locus) preclinical [651] 
YLDV (yatapoxvirus) Oncolysis Not described GFP (TK locus) preclinical [652] 
Abbreviations: IGR3: Alternative insertion site known as intergenic region 3—located in the Hind III I region (between I3L and I4L); MUC1: Mucin-1; PSA: Prostate-specific 
antigen; PSCA: Murine prostate stem cell antigen; STEAP1: Murine six transmembrane epithelial antigen of the prostate 1; GA733 Ag: Glycoprotein GA733/CO17-
1A/EpCAM/KSA/KS1-4; AFP: A-fetoprotein; HPV: Human papillomavirus; EBNA1-LMP2: CD4 epitope-rich C-terminal domain of EBNA1 fused to full-length LMP2; 
GM-CSF: Granulocyte–macrophage colony-stimulating factor; IL-2: Interleukin 2; HER-2: Human epidermal growth factor receptor 2; hNIS: Human thyroidal sodium 
iodide symporter; ETA: Epithelial tumor antigen; CD: Cytosine deaminase; PNP: Purine nucleoside phosphorylase; FCU-1: Fusion yeast CDaseH-UPRTase gene; TFR: 
Human transferrin receptor; IFN-β: Interferon-β; CD40L: CD40 ligand; PAP: Prostate tumor-associated antigen prostatic acid phosphatase; CEA: Carcinoembryonic antigen; 
TRICOM: Costimulatory molecules (B7.1, ICAM-1 and LFA-3); GFP: Green fluorescent protein; YLDV: Yaba-like disease virus. 
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8. Future Perspectives 
Since Jenner first described in 1798 the application of a virus isolated from a cow to demonstrate the 
efficacy of vaccination against smallpox, the poxvirus family has been in constant change and under 
human-made adaptation. It was soon realized that this family of viruses was quite large and infected a 
wide range of animal species. Only the orthopoxvirus genus replicates productively in humans, with the 
variola strain being the cause of smallpox. Due to the health problems inherent in smallpox, one of the 
most dreadful diseases of human mankind with a death rate of about 30%, a major effort was dedicated 
to eradicate this scourge. It was not until 1980 that the WHO declared that the world was free of 
smallpox. Along the way, many studies aimed to understand the biology of this group of animal viruses, 
and major scientific discoveries emerged that had a profound effect on biology as a whole. In fact, 
scientific concepts as relevant as the basis of immunology and antibody responses to virus infection, the 
components of a virus particle (DNA, protein, lipids), the presence of a DNA-dependent RNA 
polymerase, the virion machinery for mRNA synthesis and modifications at the 3'-end and 5'-end, the 
formation of two forms of infectious virus particles, the existence of multiple viral genes with the 
capacity to counteract host immune responses, and the ability of the virus to accept the insertion of 
heterologous foreign genes in the viral genome or the removal of multiple viral genes, are among features 
that define the plasticity of this family of viruses, which in turn increased our knowledge of living viruses 
and cells. 
The urgency to develop attenuated vaccines promoted the use of different animal models and cell 
culture systems for virus isolation. As a result a number of vaccine strains emerged in different countries. 
It was not until whole genome sequencing was developed that we realized the occurrence of different 
genetic changes within the virus genome. Being a large DNA with a high fidelity polymerase, it was not 
surprising that, in order to observe genetic alterations such as deletions and point mutations, multiple 
passages of the virus in cell cultures were needed for attenuation. This effort resulted in the isolation and 
identification of the now most widely used poxvirus vaccine strain candidates, mainly those derived from 
NYCBH (Dryvax and ACAM2000), Lister, LC16m8, Tian Tan, MVA, NYVAC and ALVAC. 
After the first entire DNA sequence of the Copenhagen strain of VACV was described in 1990, the 
number of poxvirus whole genome sequences has increased considerably. The information provided 
facilitated the identification of mutations that correlated with an attenuated phenotype. Indeed, it was 
found that in the case of the LC16m8 strain derived from Lister, the cause of attenuation is a frame-shifting 
single nucleotide deletion in the B5R gene. Thus, the old approach of allowing the appearance of spontaneous 
mutations in the virus genome during cell passages is no longer the method of choice. In fact, as soon as 
knowledge developed on the biological role of viral genes, newly designed vectors were developed, like 
NYVAC, a vector derived from the Copenhagen strain by selective deletion of 18 open reading frames 
(ORFs). The DNA sequencing methods together with the easy method for removing or incorporating selected 
genes in the viral genome have considerably expanded our understanding of the role of viral-encoded 
immune modulators and the use of poxvirus vectors as vaccine candidates.  
Multiple vaccine candidates have been developed based on members of the poxvirus family with the 
ability to express the genes of interest in hosts of different origins. The most widely used poxvirus 
vectors are derived from MVA, NYVAC and ALVAC, and while none of these vectors has been 
approved for human usage as a virus recombinant vaccine, the promising results obtained in a large 
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number of preclinical and clinical trials presage a not-too-distant application of these recombinant viral 
vectors as vaccines in humans against multiple diseases. This is exemplified in the partial efficacy of 
ALVAC against HIV in a phase III clinical trial in Thailand, and in the recent outbreak of Ebola after 
efficacy results were observed in non-human primates with the prime/boost combination of adenovirus 
and MVA vectors expressing Ebola GP protein, a protocol that might be implemented as part of the 
phase I/II clinical trials that have been initiated at various sites in Africa. There is also abundant 
preclinical information on the proven efficacy of these vectors in other model diseases.  
What can we expect the next steps in poxvirus vaccine evolution to be? The fact that the whole virus 
genome sequence can be reconstituted through synthesis of nucleotides, that the virus genome can be 
easily manipulated genetically, and that new information on the role of viral genes and interactions with 
the host cell are known, indicate that for vaccine purposes novel vectors with high specificity to trigger 
B and T cell immune responses and with high protective capacity will be developed. Indeed, novel 
vectors triggering high immune responses against the foreign expressed antigens have been generated, 
either by selective deletion of viral immune modulators, incorporation of host range genes, incorporation 
of cytokines/chemokines genes or of other inducers/activators of immune responses. Still it is unclear if 
we just need to develop vectors that trigger very potent immune responses, i.e., high ELISPOT numbers, 
or just to select those that trigger long-term memory B and T cell responses as an index of potency. In all 
cases, efficacy will be needed in model systems, as well as definition of immune correlates of protection. 
The implementation of system biology approaches in preclinical and clinical trials, from non-human 
primates to vaccinated individuals, will identify gene signatures relevant in protection and could aid in the 
selection of optimal immunogens. Still, much remains to be learned about the biological role played by 
many of the virus-encoded immune modulators. For vaccine purposes, it will be important to advance with 
vectors that are well characterized in terms of pathogenicity, immunogenicity and molecular signatures.  
Best-in-class candidates can be defined by direct head-to-head comparison on immune characteristics among 
vectors. Since the final aim is to develop a vaccine that fully protects against a disease, this will only be 
known with the progressive advance of generating optimized poxvirus vectors and studying their behavior 
in animal models and in clinical trials. Nonetheless, it is predicted that while in some cases a single poxvirus 
recombinant vector might be sufficient to fight a disease, it is likely that in most cases heterologous vector 
combinations, like DNA, RNA, protein or other attenuated viral vectors, will be used together in prime/boost 
protocols to fight more complex diseases. Overall, we have seen remarkable changes in poxvirus evolution 
with time, from virus isolation in animals and cell cultures to selectively targeting viral genes. As more 
scientific information is gained on vector biology and preclinical and clinical trials further advance, showing 
health benefits on vectors’ behavior, we anticipate a bright future for the poxvirus-based vaccine field. 
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